{"id":"W2963476376","doi":"10.1016/s1470-2045(19)30388-2","title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1153,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"Merck Sharp and Dohme; Les Laboratories Pierre Fabre; Merck; Meso Scale Diagnostics; Roche; British Microcirculation Society; Amgen","keywords":"Ipilimumab; Pembrolizumab; Post-hoc analysis; Open label; Medicine; Post hoc; Oncology; Internal medicine; Clinical trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003135255,0.001882151,0.003397858,0.0004586636,0.0004253052,0.001381757,0.001120321,0.001658187,0.005906601],"category_scores_gemma":[0.002167792,0.0007157131,0.002810247,0.0004517135,0.001278678,0.001980364,0.0005299829,0.004250428,0.001205747],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000877868,"about_ca_system_score_gemma":0.0008404616,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001196962,"about_ca_topic_score_gemma":0.002086209,"domain_scores_codex":[0.9989416,0.0006013688,0.00004960034,0.0001629677,0.00006922303,0.000175203],"domain_scores_gemma":[0.9987789,0.0004668239,0.0002785528,0.0001016975,0.00006208794,0.0003119513],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.983634,0.00272751,0.0002108085,0.0004216694,0.0007545332,0.00001867505,0.0000305821,0.0003089301,0.001573638,0.00005016556,0.0003689955,0.009900494],"study_design_scores_gemma":[0.934469,0.06183074,0.001931321,0.00003358276,0.0005731414,0.00002240121,0.00002399324,0.0003209599,0.0003059383,0.0001095999,0.0003644737,0.00001488106],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856907,0.006419362,0.0009340206,0.0006387478,0.0006134927,0.001980607,0.00128399,0.0001411258,0.002297976],"genre_scores_gemma":[0.9859838,0.0035911,0.001650907,0.001094808,0.0005304482,0.001894575,0.001375659,0.00004622949,0.003832437],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005906601,"threshold_uncertainty_score":0.0197596,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04835099458072202,"score_gpt":0.3901170919169451,"score_spread":0.3417660973362231,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}